Suppr超能文献

立体定向分次伽玛刀放射外科治疗:良性和恶性颅内肿瘤的机构经验。

Hypofractionated Gamma Knife Radiosurgery: Institutional Experience on Benign and Malignant Intracranial Tumors.

机构信息

Department of Neurosurgery, Trauma Center, Gamma Knife Center, Cannizzaro Hospital, Catania, Italy.

Department of Neurosurgery Highly Specialized Hospital of National Importance "Garibaldi", Catania, Italy.

出版信息

Anticancer Res. 2022 Apr;42(4):1851-1858. doi: 10.21873/anticanres.15661.

Abstract

BACKGROUND/AIM: We investigated the treatment outcomes and complications associated with hypofractionated GKRS for the treatment of benign and malignant intracranial tumors.

PATIENTS AND METHODS

Patients with intracranial tumors not candidate or refusing surgery were evaluated to assess eligibility to undergo hypofractionated Gamma Knife radiosurgery (GKRS). Targeted volumes were calculated using the GammaPlan workstation, and GKRS protocols were delivered with 3 or 5 daily fractions and a maximal total dose of 25 Gy. The thermoplastic mask was used to immobilize the patient's head without pin-based fixation frames.

RESULTS

A total of 41 patients, affected with 6 different histologies, were treated and followed-up for a median of 12 months (range=4-24 months). Meningiomas were the most common tumors (33, 80.5%), followed by brain metastases (4, 9.7%). At last follow-up, 33 patients (80.5%) had stable disease, 8 tumor regression (19.5%), and 0 tumor progression. No acute radiation toxicity was observed. Death was reported in 3 patients (7.3%) due to malignant tumor progression.

CONCLUSION

Our hypofractionated GKRS protocol proved to be effective and safe in the treatment of patients with benign and malignant intracranial tumors. Local tumor control was achieved in all patients, with 8 patients showing tumor regression and no cases of acute radiation toxicity.

摘要

背景/目的:我们研究了分次伽玛刀放射外科治疗(GKRS)治疗颅内良恶性肿瘤的治疗效果和相关并发症。

患者和方法

评估了不适合手术或拒绝手术的颅内肿瘤患者,以评估其是否适合接受分次伽玛刀放射外科治疗(GKRS)。使用 GammaPlan 工作站计算目标体积,并使用 3 或 5 个每日分次和最大总剂量 25Gy 进行 GKRS 治疗。使用热塑面罩固定患者头部,无需使用基于销钉的固定框架。

结果

共有 41 例患者,6 种不同组织学类型的肿瘤,接受治疗并随访中位数为 12 个月(范围=4-24 个月)。脑膜瘤是最常见的肿瘤(33 例,80.5%),其次是脑转移瘤(4 例,9.7%)。末次随访时,33 例(80.5%)患者疾病稳定,8 例肿瘤消退(19.5%),0 例肿瘤进展。未观察到急性放射毒性。3 例患者(7.3%)因恶性肿瘤进展而死亡。

结论

我们的分次 GKRS 方案在治疗颅内良恶性肿瘤患者中是有效和安全的。所有患者均达到局部肿瘤控制,8 例患者肿瘤消退,无急性放射毒性病例。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验